Regeneron Pharmaceuticals Inc (NASDAQ:REGN) released multiple ascending dose (MAD) data from a Phase 1 study evaluating garetosmab (anti-activin A) and trevogrumab (anti-myostatin) on body composition in healthy volunteers (n=34) at the American Diabetes Association meeting. The data demonstrated that combination therapy led to greater-than-additive increases in lean mass while decreasing fat mass in healthy participants. Thigh muscle volume (TMV) increased from baseline 7.7% with trevogrumab 6 mg/kg + garetosmab 10 mg/kg (vs. placebo) and 4.6% with trevogrumab 6 mg/kg (vs. placebo) 8 weeks after single-dose. Total fat mass and android fat mass (AFM) decreased from baseline with trevogrumab 6 mg/kg + garetosmab 10 mg/kg (-4.6% and -6.7% vs. placebo). After multiple-dose, TMV initially increased after 3 doses of trevogrumab 6 mg/kg + garetosmab 10 mg/kg but decreased to similar levels as a placebo at Week 28; AFM and visceral ...